Rothwell, Figg has an outstanding reputation in connection with pharmaceutical litigation. Our attorneys have been involved in litigation of cases arising out of the Drug Price Competition and Patent Term Restoration Act (the “Hatch-Waxman amendments”) from its inception. Trial and appellate litigation under the Hatch-Waxman amendments continues to form a large part of the firm’s litigation practice. Several partners devote nearly all of their time to pharmaceutical litigation, including cases brought under the Hatch-Waxman amendments, and to related FDA matters.
The firm has represented both brand-name pharmaceutical innovators and generic drug manufacturers. Notable cases include our representation of Burroughs Wellcome Co. in federal district courts and in the Federal Circuit in connection with challenges to patents covering AZT (Retrovir®) and of Zeneca Inc. concerning the highly successful cancer drug, Casodex®. See our listing of cases for more examples of the firm’s involvement in Hatch-Waxman litigation.